N/A
N=32
Cadmium-zinc-telluride (CZT) Imaging of Myocardial Blood Flow (MBF) (SPECT MBF)
Coronary Heart Disease
Bottom Line
View on ClinicalTrials.gov: NCT02280941 ↗Enrolled (actual)
32
Serious AEs
0.0%
Results posted
Apr 2025
Primary outcome: Primary: Difference Between Measurements of Myocardial Blood Flow Measured With PET and With SPECT — 0.06 mean residual difference in MBF
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- single photon emission computed tomography (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Ottawa Heart Institute Research Corporation
- Primary completion
- Sep 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Difference Between Measurements of Myocardial Blood Flow Measured With PET and With SPECT |
0.06 | — |
| PRIMARY Precision of Myocardial Blood Flow Measurements Between Two SPECT Scans |
29.5 | — |
Summary
This study is being done to compare the blood flow measurements obtained with the SPECT and PET imaging scans. Measurements such as myocardial blood flow (MBF) and myocardial flow reserve (MFR) are analyzed on PET scans. These measurements give the doctors more precise information in diagnosing heart problems. SPECT scans, with new camera technology and computer software, now have the potential to also give this additional information. The study is investigating how well the blood flow measurements from SPECT compared to PET.
Eligibility Criteria
Inclusion Criteria
For all participants
- Age ≥ 18 years old
- BMI ≤ 40 kg/m2
- Able and willing to comply with the study procedures
- Written informed consent Participants with intermediate to high probability of CAD
- Suspected or known CAD on a stable medication regime. Healthy volunteers without known heart disease
- Low risk of CAD (ACC Guidelines Pre-test Probability of Coronary Disease by Symptoms, Gender and Age)
Exclusion Criteria
- History or risk of severe bradycardia (heart rate < 50 beats per minute) not related to chronotropic drugs
- Known second- or third-degree AV block without pacemaker
- Dyspnea (NYHA III/IV), wheezing asthma or COPD
- Coronary artery bypass graft (CABG) surgery within 60 days prior to screening or at any time after consent
- Percutaneous coronary intervention (PCI) within 30 days prior to screening or at any time following consent
- Acute myocardial infarction or acute coronary syndrome within 60 days prior to screening or at any time following consent
- Recent use of dipyridamole, dipyridamole-containing medications (e.g. Aggrenox)
- Known hypersensitivity to dipyridamole
- Breastfeeding or pregnancy
- Claustrophobia or inability to lie still in a supine position
- Unwillingness or inability to provide informed consent
Data sourced from ClinicalTrials.gov (NCT02280941). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.